Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells.

Abstract

Tumor therapy escape due to undesired side effects induced by treatment, such as prosurvival autophagy or cellular senescence, is one of the key mechanisms of resistance that eventually leads to tumor dormancy and recurrence. Glioblastoma is the most frequent and practically incurable neoplasm of the central nervous system; thus, new treatment modalities have been investigated to find a solution more effective than the currently applied standards based on temozolomide. The present study examined the newly synthesized compounds of aziridine-hydrazide hydrazone derivatives to determine their antineoplastic potential against glioblastoma cells in vitro. Although the output of our investigation clearly demonstrates their proapoptotic activity, the cytotoxic effect appeared to be blocked by treatment-induced autophagy, the phenomenon also detected in the case of temozolomide action. The addition of an autophagy inhibitor, chloroquine, resulted in a significant increase in apoptosis triggered by the tested compounds, as well as temozolomide. The new aziridine-hydrazide hydrazone derivatives, which present cytotoxic potential against glioblastoma cells comparable to or even higher than that of temozolomide, show promising results and, thus, should be further investigated as antineoplastic agents. Moreover, our findings suggest that the combination of an apoptosis inducer with an autophagy inhibitor could optimize chemotherapeutic efficiency, and the addition of an autophagy inhibitor should be considered as an optional adjunctive therapy minimizing the risk of tumor escape from treatment.

• Authors: Monika Witusik-Perkowska, Pola Głowacka, Adam M Pieczonka, Ewa Świderska, Agnieszka Pudlarz, Michał Rachwalski, Julia Szymańska, Magdalena Zakrzewska, Dariusz J Jaskólski, Janusz Szemraj
• Journal: Cells (Cells) Vol. 12 Issue 14 (07 21 2023) ISSN: 2073-4409 [Electronic] Switzerland
• PMID: 37508570 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Temozolomide
• Chloroquine
• Hydrazones
• Hydrazines
• Antineoplastic Agents
• Aziridines

Topics

• Humans
• Glioblastoma (drug therapy, pathology)
• Temozolomide (pharmacology, therapeutic use)
• Chloroquine (pharmacology)
• Hydrazones (pharmacology)
• Hydrazines (pharmacology)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Autophagy
• Aziridines (pharmacology, therapeutic use)